123 related articles for article (PubMed ID: 37121360)
21. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Wu FQ; Fang T; Yu LX; Lv GS; Lv HW; Liang D; Li T; Wang CZ; Tan YX; Ding J; Chen Y; Tang L; Guo LN; Tang SH; Yang W; Wang HY
J Hepatol; 2016 Aug; 65(2):314-24. PubMed ID: 27154061
[TBL] [Abstract][Full Text] [Related]
22. Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells.
Rodríguez-Hernández MA; de la Cruz-Ojeda P; Gallego P; Navarro-Villarán E; Staňková P; Del Campo JA; Kučera O; Elkalaf M; Maseko TE; Červinková Z; Muntané J
Biochem Pharmacol; 2020 Jun; 176():113902. PubMed ID: 32156660
[TBL] [Abstract][Full Text] [Related]
23. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
24. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Yang PM; Lin LS; Liu TP
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661
[TBL] [Abstract][Full Text] [Related]
26. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
27. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
28. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
29. CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.
Gao Y; Fan X; Li N; Du C; Yang B; Qin W; Fu J; Markowitz GJ; Wang H; Ma J; Cheng S; Yang P
Pharmacol Res; 2020 Jul; 157():104800. PubMed ID: 32278046
[TBL] [Abstract][Full Text] [Related]
30. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
31. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
32. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Nour MA; Kheradmand F; Rasmi Y; Baradaran B
Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
[TBL] [Abstract][Full Text] [Related]
33. PRMT6 deficiency induces autophagy in hostile microenvironments of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability.
Che N; Ng KY; Wong TL; Tong M; Kau PW; Chan LH; Lee TK; Huen MS; Yun JP; Ma S
Cancer Lett; 2021 Mar; 501():247-262. PubMed ID: 33186656
[TBL] [Abstract][Full Text] [Related]
34. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
35. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
Zhou T; Li S; Xiang D; Liu J; Sun W; Cui X; Ning B; Li X; Cheng Z; Jiang W; Zhang C; Liang X; Li L; Cheng X; Hui L; Wang H; Ding J
Signal Transduct Target Ther; 2020 Dec; 5(1):296. PubMed ID: 33361765
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
[TBL] [Abstract][Full Text] [Related]
38. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
[TBL] [Abstract][Full Text] [Related]
39. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
40. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
